591P Survival and benefit of adjuvant chemotherapy (ACT) by circulating tumor DNA (ctDNA)-based genomic profile and molecular residual disease (MRD) in resectable colorectal oligometastases (CRM): PRECISION, a prospective multicenter studyShin Kobayashi, Yoshiaki Nakamura, Manabu Shiozawa et al.|Annals of Oncology|2023Cited by 5
Characteristics of patients (pts) with disease relapse despite absence of molecular residual disease (MRD) after resection of colorectal oligometastases (CRM): Implications from PRECISION study.Shin Kobayashi, Yoshiaki Nakamura, Takeshi Takamoto et al.|Journal of Clinical Oncology|2024Cited by 0